Obiltoxaximab

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Obiltoxaximab
Accession Number
DB05336
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

Protein chemical formula
Not Available
Protein average weight
148000.0 Da
Sequences
Not Available
Synonyms
Not Available
External IDs
ETI-204
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AnthimSolution100 mg/1mLIntravenousElusys Therapeutics, Inc.2016-03-18Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
29Z5DNL48C
CAS number
1351337-07-9

Pharmacology

Indication

Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Obiltoxaximab.
AbituzumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Obiltoxaximab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Obiltoxaximab.
AducanumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Obiltoxaximab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Obiltoxaximab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab.
AlirocumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Alirocumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun. 2005 Feb;73(2):795-802. [PubMed:15664918]
External Links
PubChem Substance
347910089
Wikipedia
Obiltoxaximab
ATC Codes
J06BB22 — Obiltoxaximab
FDA label
Download (315 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherInhaled anthrax caused by Bacillus anthracis4
1CompletedTreatmentAnthrax1
1CompletedTreatmentBacillus Anthracis (Anthrax)1
1CompletedTreatmentHealthy Volunteers1
4Not Yet RecruitingTreatmentAnthrax / Bacterial Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravenous100 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:23 / Updated on July 13, 2019 00:45